KRAS mutant lung cancer: progress thus far on an elusive therapeutic target
Open Access
- 14 December 2015
- journal article
- review article
- Published by Wiley in Clinical and Translational Medicine
- Vol. 4 (1) , 35
Abstract
The KRAS mutation remains the most common driver mutation in patients with non‐small cell lung cancer (NSCLC) and confers a poor prognosis. Thus far, efforts to target this mutation over the last two decades have been unsuccessful. Over the past 5 years, many efforts to develop drugs that target the RAS‐RAF‐MEK‐ERK (MAPK) pathway have resulted in enhanced understanding of the KRAS mutant NSCLC and have provided optimism that this disease can be targeted.Keywords
Funding Information
- LUNGevity Foundation
- V Foundation for Cancer Research
- Sidney Kimmel Foundation for Cancer Research
- Doris Duke Charitable Foundation
- LUNGevity Foundation
- National Cancer Institute (P50 CA9045440)
- V Foundation
- Sidney Kimmel Foundation for Cancer Research
- Doris Duke Charitable Foundation
This publication has 53 references indexed in Scilit:
- Prognostic and Predictive Value of KRAS Mutations in Advanced Non-Small Cell Lung CancerPLOS ONE, 2013
- LKB1 Inactivation Dictates Therapeutic Response of Non-Small Cell Lung Cancer to the Metabolism Drug PhenforminCancer Cell, 2013
- A Comprehensive Survey of Ras Mutations in CancerCancer Research, 2012
- A murine lung cancer co-clinical trial identifies genetic modifiers of therapeutic responseNature, 2012
- Effect of KRAS Oncogene Substitutions on Protein Behavior: Implications for Signaling and Clinical OutcomeJNCI: Journal of the National Cancer Institute, 2012
- Hsp90 Molecular Chaperone Inhibitors: Are We There Yet?Clinical Cancer Research, 2012
- Exploiting Cancer Cell Vulnerabilities to Develop a Combination Therapy for Ras-Driven TumorsCancer Cell, 2011
- Evaluation of KRAS Mutations, Angiogenic Biomarkers, and DCE-MRI in Patients with Advanced Non–Small-Cell Lung Cancer Receiving SorafenibClinical Cancer Research, 2011
- COSMIC: mining complete cancer genomes in the Catalogue of Somatic Mutations in CancerNucleic Acids Research, 2010
- A Synthetic Lethal Interaction between K-Ras Oncogenes and Cdk4 Unveils a Therapeutic Strategy for Non-small Cell Lung CarcinomaCancer Cell, 2010